CytomX Therapeutics, Inc. Stock Issued During Period, Shares, Employee Stock Purchase Plans
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CytomX Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for the quarter ending 2017-12-31 was 24.71K shares.
- CytomX Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for the quarter ending 2017-09-30 was 0.00 shares.
- CytomX Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2024 was 383.35K shares, a 5.80% decline from fiscal 2023.
- CytomX Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2023 was 406.93K shares, a 0.43% increase from fiscal 2022.
- CytomX Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2022 was 405.19K shares, a 120.37% increase from fiscal 2021.
- CytomX Therapeutics, Inc. stock issued during period, shares, employee stock purchase plans for fiscal 2021 was 183.87K shares, a 42.88% increase from fiscal 2020.
| Period end | Stock Issued During Period, Shares, Employee Stock Purchase Plans 3 month | Stock Issued During Period, Shares, Employee Stock Purchase Plans 12 month |
|---|---|---|
| 2024-12-31 | 383.35K shares 10-K · filed 2025-03-06 | |
| 2023-12-31 | 406.93K shares 10-K · filed 2025-03-06 | |
| 2022-12-31 | 405.19K shares 10-K · filed 2024-03-11 | |
| 2021-12-31 | 183.87K shares 10-K/A · filed 2023-03-27 | |
| 2020-12-31 | 128.68K shares 10-K/A · filed 2023-03-27 | |
| 2019-12-31 | 142.95K shares 10-K · filed 2021-02-24 | |
| 2018-12-31 | 63.92K shares 10-K · filed 2020-02-27 | |
| 2017-12-31 | 24.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | 67.75K shares 10-K · filed 2019-02-27 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | |
| 2016-12-31 | 31.56K shares 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |